- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00209547
Study to Assess Safety and Efficacy of AQUAVAN® Injection for Sedation During Cardiac Catheterization
A Phase III, Randomized, Open-Label Study to Assess the Safety and Efficacy of AQUAVAN® Injection Versus Midazolam HCl for Sedation in Patients Undergoing Percutaneous Coronary (PC) Procedures
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This was a randomized, open-label study designed to assess the safety and efficacy of AQUAVAN® Injection (hereafter referred to as AQUAVAN) versus the reference drug, midazolam HCl (hereafter referred to as midazolam) following pretreatment with fentanyl citrate injection (hereafter referred to as fentanyl) in producing sedation in male and female patients undergoing single PC procedures.
Screening assessments were done within 2 weeks of scheduled procedures. After completion of preprocedural sedation assessments, patients were randomly assigned to 1 of the 2 treatment groups at a 3:1 (AQUAVAN: midazolam) allocation ratio on the day of the scheduled procedure (Day 0) via an Interactive Voice Response System (IVRS). Randomization was stratified by site.
All patients, regardless of treatment group assignment, received fentanyl as an analgesic pretreatment. Supplemental doses of fentanyl could be administered if the patient reported pain or if analgesia was inadequate, as demonstrated by increased heart rate and/or blood pressure in the presence of adequate sedation. At no time was fentanyl to be administered to increase sedation levels.
AQUAVAN or midazolam was administered by intravenous (i.v.) bolus to induce a state of minimal-to-moderate (procedural) s sedation, defined as a score of ≤4 on the Modified Observer's Assessment of Alertness/Sedation (OAA/S) scale. Supplemental doses were administered, if necessary, to increase the depth or duration of sedation. Supplemental doses were not administered if the Modified OAA/S score was ≤2 or if there was no purposeful response to stimulation. Patient and Investigator assessments were used to confirm that the depth of sedation met the goals of sedation, reduced anxiety, and awareness.
Follow-up patient assessments were conducted in a telephone interview 24 hours following treatment and during a clinic visit 2 to 5 days following treatment.
Study Type
Enrollment
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient provided signed/dated Informed Consent and HIPAA authorization after receiving a full explanation of the extent and nature of the study.
- Patient was at least 18 years of age at the time of screening (Prior to Amendment 2 [dated 04 February 2005], the patient was required to be between 18 and 65 years of age, inclusive. Three subjects were randomized under this earlier inclusion criteria).
- If female, patient was surgically sterile, postmenopausal or not pregnant or lactating and had been using an acceptable method of birth control for at least 1 month prior to dosing, with a negative urine pregnancy test result at Screening and Predosing Periods.
- Patient met American Society of Anesthesiologists (ASA)13, 14 Physical Status Classification System level I to III; and
- Patient was an inpatient or outpatient scheduled to undergo a single PC procedure.
Exclusion Criteria:
- Patient had history of allergic reaction or hypersensitivity to any anesthetic agent, narcotic, or benzodiazepine.
- Patient did not meet nils per os (NPO) status per ASA Guideline or institution's guideline.
- Patient had a condition(s) that, in the opinion of the Investigator, could interfere with appropriate airway management.
- Patient had participated in an investigational drug study within 1 month prior to study start.
- Patient had history of mental or visual impairment that would not permit successful measurement of cognitive evaluations.
- Patient was unwilling to adhere to pre- and postprocedural instructions; or
- Patient for whom the use of fentanyl or midazolam was contraindicated.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Demonstrate that AQUAVAN was effective in providing adequate sedation in patients undergoing percutaneous coronary (PC) procedures.
|
Secondary Outcome Measures
Outcome Measure |
---|
Treatment-emergent adverse events, Sedation-related adverse events, and airway Assistance.
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: James Jones, MD,PharmD, Eisai Inc.
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 3000-0411
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Angioplasty
-
University Hospital, ToulouseCompletedAngioplastySpain, Russian Federation, Italy, France, Austria, Germany, Greece, Poland
-
Ralf Degenhardt, PhDB. Braun Melsungen AGCompleted
-
Indus Hospital and Health NetworkCompletedAngioplasty | CoronaryPakistan
-
Weill Medical College of Cornell UniversityCompletedAngioplasty PatientsUnited States
-
French Cardiology SocietyCompletedIntracoronary AngioplastyFrance
-
Association de Musicothérapie Applications et Recherches...American Hospital of ParisCompleted
-
Klinik für Kardiologie, Pneumologie und AngiologieRecruiting
-
University of PatrasCompleted
-
Weill Medical College of Cornell UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedAngioplasty PatientsUnited States
-
Weill Medical College of Cornell UniversityCompletedAngioplasty PatientsUnited States
Clinical Trials on fospropofol disodium
-
West China HospitalCompleted
-
Eisai Inc.Omnicare Clinical Research; MDS Pharma Services; Bio Analytical Research Corporation and other collaboratorsCompletedColonoscopy | Colon Polyps
-
Eisai Inc.CompletedIntubation | Respiration, Artificial | Postoperative SedationUnited States
-
Eisai Inc.CompletedAnesthesia | BronchoscopyUnited States
-
Eisai Inc.PPD; Covance; Quest Pharmaceutical ServicesTerminated
-
Eisai Inc.PPD; Covance; Quest Pharmaceutical ServicesTerminated
-
Eisai Inc.PPD; MDS Pharma Services; Bio Analytical Research Corporation; Coghlan Group (Plasma...CompletedColonoscopy | Colon Polyps
-
Eisai Inc.PPD; CovanceTerminatedOsteotomy | Carpal Tunnel | Arthroscopy | Bunionectomy
-
Eisai Inc.CompletedProcedural SedationUnited States